+44 20 8123 2220
info@marketpublishers.com

Global Metachromatic Leukodystrophy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

https://marketpublishers.com/r/GDE1047B7D8EN.html
Date: August 2019
Pages: 43
Price: US$ 1,799.00 (Single User License)
ID: GDE1047B7D8EN

Abstracts

High levels of pipeline activity are being observed in Metachromatic Leukodystrophy treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including ArmaGen Inc, Homology Medicines Inc, Recursion Pharmaceuticals Inc, RegenxBio Inc, Takeda Pharmaceutical Company Ltd and others.

A Significant contribution to the Metachromatic Leukodystrophy pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Metachromatic Leukodystrophy pipeline included 7 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Metachromatic Leukodystrophy condition and increased access to investments is encouraging growth of Metachromatic Leukodystrophy drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Metachromatic Leukodystrophy drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Metachromatic Leukodystrophy therapeutic candidates. Further, drugs in clinical stage

+44 20 8123 2220
info@marketpublishers.com

including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Metachromatic Leukodystrophy pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Metachromatic Leukodystrophy. Further, orphan drug status, fast track designation, grants awarded and other special status for Metachromatic Leukodystrophy pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Metachromatic Leukodystrophy pipeline and formulate effective research and development strategies.

RESEARCH METHODOLOGY

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Metachromatic Leukodystrophy Pipeline candidates-

Pre-clinical Phase: Discovery, research, pre-clinical

Early Phase: Phase 1 and Phase 2 Metachromatic Leukodystrophy drugs

Late phase: Phase 3 and in-approval Metachromatic Leukodystrophy drugs

Companies involved in the Pipeline-

Company overview

+44 20 8123 2220
info@marketpublishers.com

- Snapshot
- Metachromatic Leukodystrophy therapeutic treatment activities

Details for each Metachromatic Leukodystrophy drug candidate-

- Snapshot
  - Drug Name
  - Alternative Names
  - Company
  - Originator
  - Phase
  - Molecule Type
  - Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details

Other details

- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate

+44 20 8123 2220
info@marketpublishers.com

Recent Metachromatic Leukodystrophy therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Metachromatic Leukodystrophy Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

Product link: https://marketpublishers.com/r/GDE1047B7D8EN.html

Price: US$ 1,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GDE1047B7D8EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com